
Home » ELAN SIGNS LICENSE AGREEMENT WITH ABBOTT FOR ELAN'S PROPRIETARY NANOCRYSTAL TECHNOLOGY
ELAN SIGNS LICENSE AGREEMENT WITH ABBOTT FOR ELAN'S PROPRIETARY NANOCRYSTAL TECHNOLOGY
Elan Corporation, plc today announced that it has entered into a License Agreement with Abbott Pharmaceutical PR Ltd in which Abbott has been granted US rights, in a partnership with AstraZeneca Pharmaceuticals, LP, to utilize Elan' proprietary NanoCrystal Technology to develop and commercialize a single fixed-dose combination product containing the active pharmaceutical ingredients in Abbott's TriCor145 (fenofibrate) and AstraZeneca's Crestor (rosuvastatin calcium) products. Business Wire (http://home.businesswire.com/portal/site/home/?epi_menuItemID=989a6827590d7dda9cdf6023a0908a0c&epi_menuID=c791260db682611740b28e347a808a0c&epi_baseMenuID=384979e8cc48c441ef0130f5c6908a0c&ndmViewId=news_view&newsLang=en&div=1192646576&newsId=20060705005965)
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
01Feb
-
08Feb
-
09Feb
-
15Feb
-
16Feb
-
22Feb